Shared on04 Aug 25Fair value Increased 6.09%
The upward revision in Dr. Lal PathLabs’ consensus price target is primarily driven by improved revenue growth forecasts, while valuation multiples remain steady, resulting in the fair value increasing from ₹3,096 to ₹3,269. What's in the News Upcoming board meeting to consider and approve Q1 FY2025-26 unaudited standalone and consolidated financial results.
Shared on23 Apr 25Fair value Decreased 0.061%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Decreased 0.20%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.031%
AnalystConsensusTarget has decreased revenue growth from 13.7% to 12.3%.
Shared on02 Apr 25Fair value Increased 2.36%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25Fair value Decreased 0.38%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Decreased 0.82%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.